Developments at the FDA and greater physician acceptance of biosimilars made 2017 a banner year for emerging therapies, according to James Stevenson, PharmD, FASHP, professor of clinical pharmacy at the University of Michigan College of Pharmacy.
Developments at the FDA and greater physician acceptance of biosimilars made 2017 a banner year for emerging therapies, according to James Stevenson, PharmD, FASHP, professor of clinical pharmacy at the University of Michigan College of Pharmacy.
In an interview with The Center for Biosimilars®, Stevenson welcomed the FDA’s long-awaited draft guidance on demonstrating interchangeability of a biosimilar with its reference: “The industry’s really been waiting for that for a long time, so having that finally written down was, I think, a big step forward,” said Stevenson. “Understandably, [interchangeability is] still on a case-by-case basis with the manufacturer working with the FDA, but it at least provides a foundation for an interchangeability designation” in the future.
However, Stevenson added that the US emphasis on interchangeability may be somewhat misguided. “I think ultimately we’ll probably end up looking back and regretting that we had 2 designations, a biosimilar designation and an interchangeable biosimilar designation.” The true goal of treating a patient with a biosimilar is to produce the same clinical efficacy and safety as a reference product would, “and all biosimilars should be able to meet that,” said Stevenson, adding that a more appropriate focus might be conducting adequate studies and having detailed records of real-world use made available.
Greater physician acceptance of biosimilars over the past year was a welcome development for Stevenson, however. He sees the growing willingness to consider using biosimilars reflected by the fact that specialty physician organizations are beginning to issue new statements—or modify old ones—encouraging the use of biosimilars. “I think it’s primarily greater understanding of the regulatory process around biosimilars as well as greater experience with the products, particularly in Europe,” he said.
Yet 2017 also held notable disappointments: “Despite the fact that we continue to approve biosimilar drugs,” said Stevenson, “legal challenges continue to delay the introduction for many of these into practice. I was disappointed with the settlement that’s going to keep the adalimumab [Humira] biosimilar off the market until 2023. I hope we can do a better job.”
Additionally, “We’re starting to understand that payer policies are starting to have a substantial impact on the adoption of biosimilars,” said Stevenson, who is particularly concerned that some payers only authorize the use of specific biosimilars for given references (in the case of infliximab). Such a policy leads to practical problems for health systems, who may have to stock and manage 3 products in their facilities to accommodate all payer demands.
Looking ahead to 2018, “The biggest issues that I see that need to be addressed are related to legal challenges that are keeping biosimilars from reaching the marketplace,” said Stevenson, though he added that practical concerns, like pharmacovigilance, are also of interest. “It’s clear we don’t always do a great job correctly identifying the right product. My personal view is that [the situation is] going to be even worse with the naming convention that we have in the US unless all the healthcare providers really focus on the brand name.”
Strengthening the Supply Chain: Key Insights From FDA Commissioner Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
GRx+Biosims: Panelists Discuss Regulatory Shifts in Biosimilar Interchangeability
October 22nd 2024At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations in the US, discussing the FDA's new draft guidance, the removal of switching study requirements, and the need for more education to reduce misinformation and improve biosimilar uptake.